Role of ¹⁸F-FDG-PET in renal tumors: insights from WHO 2022 classification.

IF 2.1 4区医学

Japanese Journal of Radiology Pub Date : 2025-04-07 DOI:10.1007/s11604-025-01761-1

Kohei Hirota, Yoshiko Ueno, Munenobu Nogami, Toshiki Hyodo, Takahiro Tsuboyama, Keitaro Sofue, Naoya Ebisu, Takuto Hara, Izumi Imaoka, Takamichi Murakami

{"title":"Role of 18F-FDG-PET in renal tumors: insights from WHO 2022 classification.","authors":"Kohei Hirota, Yoshiko Ueno, Munenobu Nogami, Toshiki Hyodo, Takahiro Tsuboyama, Keitaro Sofue, Naoya Ebisu, Takuto Hara, Izumi Imaoka, Takamichi Murakami","doi":"10.1007/s11604-025-01761-1","DOIUrl":null,"url":null,"abstract":"The objective of this article is to provide a comprehensive overview of the imaging characteristics of various renal cell tumors using 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET), based on the latest WHO-2022 classification. Due to the physiological accumulation of FDG in the kidneys, the clinical utility of FDG-PET in the evaluation of renal tumors has traditionally been considered limited. However, recent studies have re-evaluated its potential value. FDG-PET has demonstrated particular utility in detecting metastases and postoperative recurrence of renal cell carcinoma (RCC), as well as in identifying RCC in patients with chronic kidney failure, where FDG excretion into the urinary tract is reduced. Renal tumors are occasionally detected incidentally on FDG-PET, and FDG uptake varies depending on the tumor subtype. Therefore, a comprehensive understanding of these imaging characteristics is clinically important, as it may serve as a valuable guide for subsequent diagnostic evaluations. Furthermore, recent advancements in the development of novel PET tracers hold promise for future applications in the imaging of renal tumors. We believe that the insights gained from this study will contribute to routine diagnostic practice and the planning of future research.","PeriodicalId":14691,"journal":{"name":"Japanese Journal of Radiology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11604-025-01761-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

The objective of this article is to provide a comprehensive overview of the imaging characteristics of various renal cell tumors using 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET), based on the latest WHO-2022 classification. Due to the physiological accumulation of FDG in the kidneys, the clinical utility of FDG-PET in the evaluation of renal tumors has traditionally been considered limited. However, recent studies have re-evaluated its potential value. FDG-PET has demonstrated particular utility in detecting metastases and postoperative recurrence of renal cell carcinoma (RCC), as well as in identifying RCC in patients with chronic kidney failure, where FDG excretion into the urinary tract is reduced. Renal tumors are occasionally detected incidentally on FDG-PET, and FDG uptake varies depending on the tumor subtype. Therefore, a comprehensive understanding of these imaging characteristics is clinically important, as it may serve as a valuable guide for subsequent diagnostic evaluations. Furthermore, recent advancements in the development of novel PET tracers hold promise for future applications in the imaging of renal tumors. We believe that the insights gained from this study will contribute to routine diagnostic practice and the planning of future research.

查看原文本刊更多论文

18F-FDG-PET在肾肿瘤中的作用：来自WHO 2022分类的见解

本文的目的是基于最新的WHO-2022分类，对各种肾细胞肿瘤使用18f -氟脱氧葡萄糖(FDG)-正电子发射断层扫描（PET）的成像特征进行全面概述。由于FDG在肾脏中的生理蓄积，FDG- pet在肾脏肿瘤评估中的临床应用传统上被认为是有限的。然而，最近的研究重新评估了它的潜在价值。FDG- pet在检测肾细胞癌（RCC）的转移和术后复发以及慢性肾衰竭患者的RCC方面已被证明具有特殊的实用性，在慢性肾衰竭患者中，FDG排泄到尿路的减少。FDG- pet偶尔会检测到肾脏肿瘤，FDG摄取随肿瘤亚型的不同而变化。因此，全面了解这些影像学特征在临床上非常重要，因为它可以作为后续诊断评估的有价值指导。此外，新型PET示踪剂的最新进展为肾脏肿瘤成像的未来应用带来了希望。我们相信从这项研究中获得的见解将有助于常规诊断实践和未来研究的规划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese Journal of Radiology Medicine-Radiology, Nuclear Medicine and Imaging

自引率

4.80%

发文量

133

期刊介绍： Japanese Journal of Radiology is a peer-reviewed journal, officially published by the Japan Radiological Society. The main purpose of the journal is to provide a forum for the publication of papers documenting recent advances and new developments in the field of radiology in medicine and biology. The scope of Japanese Journal of Radiology encompasses but is not restricted to diagnostic radiology, interventional radiology, radiation oncology, nuclear medicine, radiation physics, and radiation biology. Additionally, the journal covers technical and industrial innovations. The journal welcomes original articles, technical notes, review articles, pictorial essays and letters to the editor. The journal also provides announcements from the boards and the committees of the society. Membership in the Japan Radiological Society is not a prerequisite for submission. Contributions are welcomed from all parts of the world.